Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
The combination of the CAR T-cell therapy axicabtagene ciloleucel and atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Source: OncLive